Wayne State University
Medical Student Research Symposium

School of Medicine

March 2020

Induction Immunosuppression With Thymoglobulin May Improve
Graft Outcomes Without Increasing A Risk For Infection In
Patients Undergoing Liver Transplantation Alone
Matthew Henry
gf3735@wayne.edu

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Henry, Matthew, "Induction Immunosuppression With Thymoglobulin May Improve Graft Outcomes
Without Increasing A Risk For Infection In Patients Undergoing Liver Transplantation Alone" (2020).
Medical Student Research Symposium. 43.
https://digitalcommons.wayne.edu/som_srs/43

This Research Abstract is brought to you for free and open access by the School of Medicine at
DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an
authorized administrator of DigitalCommons@WayneState.

Induction Immunosuppression With Thymoglobulin May Improve Graft Outcomes Without Increasing
A Risk For Infection In Patients Undergoing Liver Transplantation Alone
2

1

1

2

1

1

1

Author Block M. Henry , S. Nagai , , T. Kitajima , J. Konel , S. Yeddula , M. Rizzari , K. Collins , D.
1
1
1
Moonka , A. Yoshida , M. Abouljoud , 1Henry Ford Hospital, Detroit, MI, 2Wayne State University School of
Medicine, Detroit, MI
Abstract:
*Purpose: Immunosuppression protocol for liver transplant (LT) varies between institutions and roles of
induction immunosuppression in LT remain controversial. The aim of this study was to compare outcomes of
primary LT patients based on the induction immunosuppression regimens, including thymoglobulin (rATG),
basiliximab, and steroids.
*Methods: We retrospectively reviewed medical charts of 166 patients who underwent LT alone from 2017
through 2018 at a single institution. Patients were divided into three groups based on the type of induction
immunosuppression utilized, and the outcomes were compared across groups. Survival was evaluated using
the Kaplan-Meier method. Multivariable Cox regression was performed to identify potential predictors of postLT graft loss. Incidence of rejection was analyzed using Gray test by considering rejection episode and graft
loss as competing risk events.
*Results: During the study period, 56, 58, and 52 patients received rATG, basiliximab, and steroids only for
induction immunosuppression. Tacrolimus, mycophenolate mofetil, and steroids were used for maintenance
immunosuppression in all three groups. The age of the rATG group was significantly lower than the other two
groups (P<0.001). The incidence rate of bacteremia (P=0.312), Clostridium difficile (P=0.779),
Cytomegalovirus (P=0.903), Epstein-barr Virus (P=0.332), and fungemia (P=0.349) were similar across the
three groups. Graft survival rate was significantly better in the rATG group compared to basiliximab (P=0.025)
and solumedrol (P=0.003) (Figure a) After adjusting the risk by the patient’s age and MELD score utilizing a
multivariate Cox regression analysis, rATG showed significantly lower risk of graft loss compared to the
steroids group (hazard ratio 6.66, P=0.037), whereas risk was similar between the rATG and basiliximab
groups (hazard ratio 3.99, P=0.111). Gray’s test showed no significant difference between the cumulative
incidence rates of biopsy proven rejections between three groups (Figure b).

*Conclusions: Patients undergoing LT alone with rATG for induction immunosuppression may have
improved liver graft survival compared to patients who received basiliximab or steroids only. The risk of
infection and incidence rates of biopsy proven rejection does not seem to be affected by induction
immunosuppression regimens. Further studies are necessary to determine this relationship.

